Single-dose azithromycin for child growth in Burkina Faso: a randomized controlled trial.


Journal

BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804

Informations de publication

Date de publication:
17 03 2021
Historique:
received: 09 12 2020
accepted: 08 03 2021
entrez: 18 3 2021
pubmed: 19 3 2021
medline: 28 5 2021
Statut: epublish

Résumé

In lower resource settings, previous randomized controlled trials have demonstrated evidence of increased weight gain following antibiotic administration in children with acute illness. We conducted an individually randomized trial to assess whether single dose azithromycin treatment causes weight gain in a general population sample of children in Burkina Faso. Children aged 8 days to 59 months were enrolled in November 2019 and followed through June 2020 in Nouna Town, Burkina Faso. Participants were randomly assigned to a single oral dose of azithromycin (20 mg/kg) or matching placebo. Anthropometric measurements were collected at baseline and 14 days and 6 months after enrollment. The primary anthropometric outcome was weight gain velocity in g/kg/day from baseline to 14 days and 6 months in separate linear regression models. Of 450 enrolled children, 230 were randomly assigned to azithromycin and 220 to placebo. Median age was 26 months (IQR 16 to 38 months) and 51% were female. At 14 days, children in the azithromycin arm gained a mean difference of 0.9 g/kg/day (95% CI 0.2 to 1.6 g/kg/day, P = 0.01) more than children in the placebo arm. There was no difference in weight gain velocity in children receiving azithromycin compared to placebo at 6 months (mean difference 0.04 g/kg/day, 95% CI - 0.05 to 0.13 g/kg/day, P = 0.46). There were no significant differences in other anthropometric outcomes. Transient increases in weight gain were observed after oral azithromycin treatment, which may provide short-term benefits. ClinicalTrials.gov NCT03676751 . Registered 19/09/2018.

Sections du résumé

BACKGROUND
In lower resource settings, previous randomized controlled trials have demonstrated evidence of increased weight gain following antibiotic administration in children with acute illness. We conducted an individually randomized trial to assess whether single dose azithromycin treatment causes weight gain in a general population sample of children in Burkina Faso.
METHODS
Children aged 8 days to 59 months were enrolled in November 2019 and followed through June 2020 in Nouna Town, Burkina Faso. Participants were randomly assigned to a single oral dose of azithromycin (20 mg/kg) or matching placebo. Anthropometric measurements were collected at baseline and 14 days and 6 months after enrollment. The primary anthropometric outcome was weight gain velocity in g/kg/day from baseline to 14 days and 6 months in separate linear regression models.
RESULTS
Of 450 enrolled children, 230 were randomly assigned to azithromycin and 220 to placebo. Median age was 26 months (IQR 16 to 38 months) and 51% were female. At 14 days, children in the azithromycin arm gained a mean difference of 0.9 g/kg/day (95% CI 0.2 to 1.6 g/kg/day, P = 0.01) more than children in the placebo arm. There was no difference in weight gain velocity in children receiving azithromycin compared to placebo at 6 months (mean difference 0.04 g/kg/day, 95% CI - 0.05 to 0.13 g/kg/day, P = 0.46). There were no significant differences in other anthropometric outcomes.
CONCLUSIONS
Transient increases in weight gain were observed after oral azithromycin treatment, which may provide short-term benefits.
CLINICAL TRIALS REGISTRATION
ClinicalTrials.gov NCT03676751 . Registered 19/09/2018.

Identifiants

pubmed: 33731058
doi: 10.1186/s12887-021-02601-7
pii: 10.1186/s12887-021-02601-7
pmc: PMC7967941
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azithromycin 83905-01-5

Banques de données

ClinicalTrials.gov
['NCT03676751']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

130

Références

PLoS Med. 2020 Sep 15;17(9):e1003285
pubmed: 32931496
N Engl J Med. 2018 Apr 26;378(17):1583-1592
pubmed: 29694816
Contemp Clin Trials Commun. 2018 Nov 29;13:100309
pubmed: 30582068
Am J Trop Med Hyg. 2020 Dec 21;:
pubmed: 33350370
Am J Trop Med Hyg. 2019 Mar;100(3):691-695
pubmed: 30608051
JAMA. 2009 Sep 2;302(9):962-8
pubmed: 19724043
JAMA Netw Open. 2020 Jan 3;3(1):e1919681
pubmed: 31968118
Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1464-9
pubmed: 12657580
Clin Infect Dis. 2019 May 30;68(12):2114-2116
pubmed: 30561577
BMJ. 2014 Apr 15;348:g2267
pubmed: 24735883
N Engl J Med. 2013 Jan 31;368(5):425-35
pubmed: 23363496
Lancet Glob Health. 2018 Dec;6(12):e1319-e1328
pubmed: 30287125
PLoS Negl Trop Dis. 2014 Sep 11;8(9):e3128
pubmed: 25210836
JAMA Pediatr. 2020 Mar 1;174(3):295-297
pubmed: 31930369
Am J Trop Med Hyg. 2019 May;100(5):1121-1124
pubmed: 30693860
Nat Med. 2019 Sep;25(9):1370-1376
pubmed: 31406349
Food Nutr Bull. 2014 Jun;35(2 Suppl):S64-70
pubmed: 25069296
Pediatr Infect Dis J. 2018 Nov;37(11):1082-1086
pubmed: 29561511
N Engl J Med. 2016 Feb 4;374(5):444-53
pubmed: 26840134
Gastroenterology. 2016 Jul;151(1):120-129.e5
pubmed: 27003602
Lancet. 2013 Aug 3;382(9890):427-451
pubmed: 23746772
Obes Rev. 2018 Nov;19(11):1463-1475
pubmed: 30035851
Trans R Soc Trop Med Hyg. 2005 Jan;99(1):6-12
pubmed: 15550255
Public Health Nutr. 2020 Feb;23(3):538-543
pubmed: 31496465
Am J Trop Med Hyg. 2013 Jan;88(1):138-143
pubmed: 23208876
PLoS Negl Trop Dis. 2019 Jun 5;13(6):e0007442
pubmed: 31166952
Lancet Glob Health. 2020 Feb;8(2):e288-e295
pubmed: 31981558
PLoS Negl Trop Dis. 2020 May 14;14(5):e0008328
pubmed: 32407313
BMC Public Health. 2014 Nov 18;14:1176
pubmed: 25407464

Auteurs

Ali Sié (A)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Boubacar Coulibaly (B)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Clarisse Dah (C)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Mamadou Bountogo (M)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Mamadou Ouattara (M)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Guillaume Compaoré (G)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Jessica M Brogdon (JM)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA.

William W Godwin (WW)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA.

Elodie Lebas (E)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA.

Thuy Doan (T)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA.
Department of Ophthalmology, University of California, San Francisco, USA.

Benjamin F Arnold (BF)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA.
Department of Ophthalmology, University of California, San Francisco, USA.

Travis C Porco (TC)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA.
Department of Ophthalmology, University of California, San Francisco, USA.
Department of Epidemiology & Biostatistics, University of California, San Francisco, USA.

Thomas M Lietman (TM)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA.
Department of Ophthalmology, University of California, San Francisco, USA.
Department of Epidemiology & Biostatistics, University of California, San Francisco, USA.

Catherine E Oldenburg (CE)

Francis I Proctor Foundation, University of California, 513 Parnassus Ave, Box 0412, San Francisco, CA, 94143, USA. catherine.oldenburg@ucsf.edu.
Department of Ophthalmology, University of California, San Francisco, USA. catherine.oldenburg@ucsf.edu.
Department of Epidemiology & Biostatistics, University of California, San Francisco, USA. catherine.oldenburg@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH